Viyash Scientific Limited’s board has approved the unaudited standalone and consolidated financial results for Q3, ending December 31, 2025. A new employee stock option scheme (ESOP), called “Viyash Scientific Limited Employee Stock Option Scheme 2026” (VSL ESOP Scheme 2026), has been introduced. There were changes to Senior Management Personnel (SMP), and some employees are designated as SMPs, effective February 5, 2026.
Financial Results Approved
Viyash Scientific Limited’s Board of Directors has approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025.
New Employee Stock Option Scheme
Based on the recommendations of the Nomination and Remuneration Committee, the Board has approved the introduction and adoption of a new employee stock option scheme called “Viyash Scientific Limited Employee Stock Option Scheme 2026” (VSL ESOP Scheme 2026). This is subject to necessary approvals.
Senior Management Changes
Changes in Senior Management Personnel (SMP) have been approved by the Board. Following organizational changes, the following employees are designated as SMPs effective February 5, 2026:
- Mr. Attanti Veera Venkata Srinivasa Rao – VP, R&D (API)
- Mr. Nrusimha Srinivasa Rao Bondalapati – VP, Quality & Regulatory
- Mr. Peddanna Gumudavelli – COO, Appco Pharma LLC, Material Subsidiary
Mr. Pradip Natarajan, previously designated as SMP, will cease to be an SMP effective February 5, 2026, but will continue to be employed by the Company.
Consolidated Financial Highlights (Q3 2026)
Key figures from the unaudited consolidated financial results:
- Revenue from Operations: ₹8,584.10 million
- Total Income: ₹8,723.90 million
- Profit Before Tax: ₹1,143.30 million
- Profit After Tax: ₹485.20 million
Standalone Financial Highlights (Q3 2026)
Key figures from the unaudited standalone financial results:
- Revenue from Operations: ₹3,416.40 million
- Total Income: ₹3,579.30 million
- Profit Before Tax: ₹518.70 million
- Profit After Tax: ₹228.40 million
Source: BSE
